Immunotherapy treatments and compositions
AssigneeSusavion Biosciences, Inc.
InventorsLaura L. Eggink, J. Kenneth Hoober
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and kits comprising a peptide that activate the immune response and methods of using the composition for immunotherapy and cancer treatments. The peptide comprises an active peptide sequence of VQATQSNQHTPR. In some embodiments, the peptide may be tetravalent. For example, the peptide has the structure [(VQATQSNQHTPRGGGS)2K]2K-NH2. In some embodiments, the compositions and methods are directed to the treatment of cancer and/or infections.
Claims23
A pharmaceutical composition, comprising a therapeutically effective amount of a peptide and a therapeutically effective amount of a first antibody, wherein the peptide has an active sequence represented by SEQ ID NO:1, and the first antibody is against a first immune checkpoint protein.
9-25. (canceled)
(canceled)
A method of activating the immune response in a subject, the method comprising:
- administering a therapeutically effective amount of a peptide to the subject, wherein the peptide has an active sequence represented by SEQ ID NO:1;
- and
- administering a therapeutically effective amount of a first antibody to the subject, wherein the first antibody is against a first immune checkpoint protein.
31-34. (canceled)
A kit for activating the immune response, the kit comprising:
- a therapeutically effective amount of a peptide, wherein the peptide has an active sequence represented by SEQ ID NO:1;
- and
- a therapeutically effective amount of one or more antibodies, wherein the antibodies are against immune checkpoint proteins.
Dependencies are inferred from the claim text.